AorTech shares marked down for seeking $92 million
This article was originally published in Clinica
Executive Summary
AorTech International, a development-stage company which just two weeks ago secured a major deal with Jomed to use its Elasteon as a stent coating, took a beating at the hands of the UK investment community. The shares were marked down when it announced it was going to the market to seek a further £64 million ($92 million) in a share offering.